


STEP 1

- Patients will be selected between 1 November 2013 and 31 October 2014 (selection period)
- Date of first prescription of a target α -blocker plus antimuscarinic or 5-ARI drug combination therapy will be defined as index date



STEP 2

- History period is defined as the 6 months before index date. This period is used to assess continuous enrolment, prior use of LUTS/BPH therapies and other characteristics
- Example: patient with index date on 31 May 2014 will be assessed from 31 November 2013 until index date

STEP 3

- Included patients will be followed-up for 12 months after index date
- Continuous enrolment until end of follow-up is required

Figure S1. Study design. 5-ARI: 5 α -reductase inhibitor; FDC: fixed-dose combination; LUTS/BPH: lower urinary tract symptoms associated with benign prostatic hyperplasia